APGE - Apogee Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$109.44
DETAILS
HIGH:
$140.00
LOW:
$83.00
MEDIAN:
$103.00
CONSENSUS:
$109.44
UPSIDE:
34.84%
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.4 | 0 | 0 | 0 |
| Gross Profit | (1.4) | 0 | 0 | 0 |
| Operating Expenses | ||||
| R&D Expenses | 214.7 | 167.9 | 68.4 | 27.8 |
| SG&A Expenses | 70.9 | 49.0 | 24.6 | 2.9 |
| Other Expenses | 0 | 0 | 0 | 0 |
| Operating Expenses | 284.2 | 216.9 | 93.0 | 30.7 |
| Operating Income | ||||
| Operating Income | (285.6) | (216.9) | (93.0) | (30.7) |
| Interest Expense | 0 | 0 | 0 | 9.2 |
| Interest Income | 30.0 | 34.7 | 9.0 | 0.1 |
| Profitability | ||||
| EBITDA | (284.2) | (216.7) | (75.0) | (39.8) |
| EBIT | (285.6) | (216.9) | (84.0) | (39.8) |
| Income Before Tax | (255.6) | (182.1) | (84.0) | (39.8) |
| Income Tax Expense | 0.3 | 0.0 | 0 | 0 |
| Net Income | (255.8) | (182.1) | (84.0) | (39.8) |
| Per Share Data | ||||
| EPS (Basic) | -4.22 | -3.30 | -1.66 | -0.79 |
| EPS (Diluted) | -4.22 | -3.30 | -1.66 | -0.79 |
| Shares Outstanding | 60.7 | 55.2 | 50.7 | 50.7 |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Current Assets | ||||
| Cash & Cash Equivalents | 131.5 | 141.8 | 118.3 | 151.9 |
| Short-Term Investments | 598.6 | 378.9 | 277.1 | 0 |
| Net Receivables | 0 | 4.7 | 1.2 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Other Current Assets | 11.2 | 1.7 | 0 | 0.1 |
| Total Current Assets | 741.4 | 529.7 | 398.4 | 152.1 |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 14.4 | 13.3 | 2.6 | 0 |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 210.4 | 0 | 0 |
| Other Non-Current Assets | 181.4 | 0.5 | 0.4 | 0 |
| Total Non-Current Assets | 195.8 | 224.2 | 3.0 | 0 |
| Total Assets | 937.1 | 754.0 | 401.4 | 152.1 |
| Current Liabilities | ||||
| Account Payables | 1.2 | 1.1 | 2.1 | 0.4 |
| Short-Term Debt | 3.5 | 3.2 | 1.1 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 23.2 | 22.4 | 17.1 | 0.5 |
| Total Current Liabilities | 27.9 | 28.6 | 20.6 | 10.0 |
| Non-Current Liabilities | ||||
| Long-Term Debt | 5.3 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities | 5.3 | 8.6 | 0.9 | 0 |
| Total Liabilities | 33.3 | 37.2 | 21.5 | 10.0 |
| Stockholders' Equity | ||||
| Common Stock | 0.0 | 0.0 | 0 | 2.3 |
| Retained Earnings | (561.8) | (305.9) | (123.8) | (39.8) |
| Accumulated Other Comprehensive Income | 1.1 | 0.9 | 0.3 | 2.1 |
| Total Stockholders' Equity | 903.9 | 716.8 | 379.9 | 142.1 |
| Total Liabilities & Equity | 937.1 | 754.0 | 401.4 | 152.1 |
| Debt Metrics | ||||
| Total Debt | 8.8 | 11.8 | 2.0 | 0 |
| Net Debt | (122.7) | (130.0) | (116.3) | (151.9) |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | (255.8) | (182.1) | (84.0) | (39.8) |
| Depreciation & Amortization | 1.4 | 0.2 | 0 | 0 |
| Stock-Based Compensation | 46.3 | 23.3 | 6.1 | 2.1 |
| Change in Working Capital | (15.5) | (2.0) | 6.1 | 9.8 |
| Other Non-Cash Items | (3.8) | (10.5) | (3.0) | 11.4 |
| Operating Cash Flow | (227.4) | (171.2) | (74.8) | (16.4) |
| Investing Activities | ||||
| Capital Expenditure | (5.1) | (1.2) | (0.2) | 0 |
| Acquisitions | 0 | 0 | 0 | 0 |
| Purchases of Investments | (642.3) | (649.5) | (303.7) | 0 |
| Sales/Maturities of Investments | 467.9 | 350.1 | 30 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (179.6) | (300.5) | (273.9) | 0 |
| Financing Activities | ||||
| Net Debt Issuance | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.6 | 0 | 0 |
| Financing Cash Flow | 396.5 | 495.1 | 315.4 | 168.3 |
| Cash Position | ||||
| Net Change in Cash | (10.5) | 23.5 | (33.3) | 151.9 |
| Cash at Beginning | 142.1 | 118.6 | 151.9 | 0 |
| Cash at End | 131.5 | 142.1 | 118.6 | 151.9 |
| Free Cash Flow | (232.6) | (172.3) | (74.9) | (16.4) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | (1.4) | 0 | 0 | 0 |
| Operating Income | (285.6) | (216.9) | (93.0) | (30.7) |
| Net Income | (255.8) | (182.1) | (84.0) | (39.8) |
| EPS (Diluted) | -4.22 | -3.30 | -1.66 | -0.79 |
| Balance Sheet | ||||
| Cash & Equivalents | 131.5 | 141.8 | 118.3 | 151.9 |
| Total Assets | 937.1 | 754.0 | 401.4 | 152.1 |
| Total Debt | 8.8 | 11.8 | 2.0 | 0 |
| Stockholders' Equity | 903.9 | 716.8 | 379.9 | 142.1 |
| Cash Flow | ||||
| Operating Cash Flow | (227.4) | (171.2) | (74.8) | (16.4) |
| Capital Expenditure | (5.1) | (1.2) | (0.2) | 0 |
| Free Cash Flow | (232.6) | (172.3) | (74.9) | (16.4) |